You just read:

Sprout Pharmaceuticals Receives Clear Guidance From FDA On Path Forward To Resubmit New Drug Application For Flibanserin, The First Potential Medical Treatment For Hypoactive Sexual Desire Disorder In Premenopausal Women

News provided by

Sprout Pharmaceuticals

Feb 11, 2014, 08:00 ET